Onyx Pharmaceuticals Inc. (ONXX) announced after the bell Wednesday that the FDA's Oncologic Drugs Advisory Committee determined by a vote of 11-0 that, in patients with relapsed and refractory multiple myeloma who have received at least two prior lines of therapy that included a proteasome inhibitor and an immunomodulatory agent, the benefit-risk assessment is favorable for the use of Kyprolis.
Onyx Pharmaceuticals has gapped open dramatically higher Wedneday and is now up 17.50 at $62.08 on strong volume. The stock has surged to a new high for the year.
For comments and feedback: editorial@rttnews.com